Last reviewed · How we verify
NCT05885269
Comparative Efficacy of Tacrolimus and Clobetasol Propionate in Alopecia Areata
Phase 1 trial testing Group A applied topical Clobetasol Propionate in Alopecia Areata in 70 participants. Completed in 30 April 2023.
30 April 2023
Quick facts
| Lead sponsor | Combined Military Hospital Abbottabad |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 70 |
| Start date | 1 November 2022 |
| Primary completion | 30 April 2023 |
| Estimated completion | 30 April 2023 |
| Sites | 1 location across Pakistan |
Drugs / interventions tested
- Group A applied topical Clobetasol Propionate — full drug profile →
- Group B applied topical Tacrolimus — full drug profile →
Conditions studied
- Alopecia Areata — all drugs for Alopecia Areata →
Sponsor
Combined Military Hospital Abbottabad
Who can join
Adults 20 to 50, any sex, with Alopecia Areata. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Methodology: The 70 patients of age 20 to 50 years presented to the out-patient department of CMH Abbottabad suffering from alopecia areata were enrolled. The non-probability consecutive sampling technique was used. Patient in group-A applied clobetasol propionate 0.05% twice daily, whereas Group-B applied topical tacrolimus 0.1% twice daily for upto 3 months. The Patients were assessed at baseline, 4th weeks, 8th week and 12th week after treatment of each session. Hair loss was calculated from SALT score at presentation and on follow-up after 3 months. The degree of response was assessed on the basis of hair re-growth as excellent (\>75% re-growth), Marked (51-75% re-growth), moderate (26-50% re-growth), or slight (≤25% re-growth). To determine statistical significance χ2-square test, taking p-value \<0.05 as significant, was used.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05885269
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Alopecia Areata
Currently open trials in the same condition.
- NCT07242638 — Treatment of Atopic Dermatitis and Alopecia Areata With Abrocitinib in Individuals With Down Syndrome · Phase 2 · recruiting
- NCT07311564 — A Study of LAD603 in Adults With Alopecia Areata · Phase 2 · recruiting
- NCT07250997 — PALLAS Laser for Skin Diseases · NA · recruiting
- NCT07205159 — A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata. · Phase 1 · recruiting
- NCT06747611 — Evaluation of Microbiota Transplant Therapy in Patients With Alopecia Areata · Phase 2 · recruiting
Other Combined Military Hospital Abbottabad trials
Trials by the same sponsor.
- NCT07331792 — Comparative Efficacy of Topical 1% Clotrimazole vs Oral Itraconazole in the Treatment of Pityriasis Versicolor · Phase 1, PHASE2 · not yet recruiting
- NCT05897112 — Comparative Efficacy of 10% Potassium Hydroxide Solution Versus Cryotherapy in Molluscum Contagiosum · Phase 1 · completed
- NCT05895071 — Comparison of Topical 5%Potassium Hydroxide vs Liquid Nitrogen in the Treatment of Plane Warts · Phase 1 · completed
- NCT05887219 — Comparison of Azelaic Acid 20 % Cream Versus Hydroquinone 4% Cream as an Adjuvant to Oral Tranexamic Acid in Melasma · Phase 1 · completed
- NCT05887232 — Comparison of Co2 Laser Versus Co2 Laser With PRP in Scars · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05885269 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Combined Military Hospital Abbottabad
- Last refreshed: 1 June 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05885269.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing